Key Points
- Insider selling: CEO Xingjuan Chao sold 25,000 shares on Dec. 1 at an average of $16.59 for $414,750 (and had sold 50,000 shares on Nov. 21 at $15.13), leaving her with 798,135 shares — a 3.04% decline in ownership.
- Shares opened at $18.00 (up 6.8%), the stock has a market cap of $667.8M and a 12‑month range of $10.01 to $32.75.
- CeriBell beat the latest quarterly EPS and revenue estimates but remains unprofitable (net margin -63.35%, ROE -29.63%); analysts are mixed with a consensus "Moderate Buy" and a $25.17 price target.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 11,112 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $12.28, for a total value of $136,455.36. Following the sale, the chief technology officer owned 167,704 shares in the company, valued at $2,059,405.12. The trade was a 6.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Raymond Woo also recently made the following trade(s):
- On Tuesday, November 11th, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $12.28, for a total transaction of $136,455.36.
- On Friday, October 3rd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48.
CeriBell Price Performance
CeriBell stock opened at $18.00 on Thursday. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $32.75. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average price of $13.12 and a 200-day moving average price of $14.37. The firm has a market capitalization of $667.80 million, a PE ratio of -11.92 and a beta of 1.35.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The company had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. As a group, equities research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current year.
Hedge Funds Weigh In On CeriBell
Large investors have recently added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC bought a new stake in shares of CeriBell in the 3rd quarter valued at about $135,000. Millennium Management LLC lifted its position in CeriBell by 41.8% during the third quarter. Millennium Management LLC now owns 666,448 shares of the company's stock valued at $7,657,000 after acquiring an additional 196,299 shares during the last quarter. Bank of America Corp DE boosted its stake in CeriBell by 87.1% in the third quarter. Bank of America Corp DE now owns 135,783 shares of the company's stock valued at $1,560,000 after acquiring an additional 63,215 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell in the third quarter worth $33,000. Finally, Two Sigma Investments LP increased its position in shares of CeriBell by 81.0% during the third quarter. Two Sigma Investments LP now owns 297,963 shares of the company's stock worth $3,424,000 after purchasing an additional 133,324 shares in the last quarter.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. decreased their price target on CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday, November 5th. TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, November 5th. Raymond James Financial started coverage on shares of CeriBell in a report on Tuesday, October 21st. They issued a "strong-buy" rating and a $19.00 price target on the stock. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of CeriBell in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $25.17.
Check Out Our Latest Report on CeriBell
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
